



08-14-2009

FORM PTO-1595 (modified)

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

103570775

To the Honorable Assistant Secretary and Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies) thereof.

1. Name of conveying party(ies): SUMITOMO CHEMICAL COMPANY, LIMITED Additional name(s) of conveying party(ies) attached? <u>NO</u>	2. Name and address of receiving party(ies): Name: <u>DAINIPPON SUMITOMO PHARMA CO., LTD.</u> Address: <u>6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka-fu, 541-8524, Japan</u> Additional name(s) & address(es) attached? <u>NO</u>
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ Execution Date: <u>May 7, 2009</u>	

4. Application number(s) or patent number(s): <u>med 8-11-09</u> If this document is being filed together with a new application, the execution date of the application is: _ A. Patent Application No. _____ B. Patent No. _____ 7,091,188, issued August 15, 2006 Additional numbers attached? <u>NO</u>	
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>WENDEROTH, LIND & PONACK, L.L.P.</u> Attn: <u>Warren M. Cheek, Esq.</u> Street Address: <u>1030 15th Street, N.W., Suite 400 East</u> City: <u>Washington</u> , State: <u>DC</u> ZIP: <u>20005-1503</u>	6. Total number of applications and patents involved: <u>1</u> 7. Total fee (37 CFR 3.41). \$40.00 <input checked="" type="checkbox"/> Enclosed (Check No. <u>90782</u>) Authorized to be charged to deposit account 8. Deposit account number: <u>23-0975</u> (Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. <u>Warren M. Cheek, Reg. No. 33,367</u> Name of Person Signing <u>Warren M. Cheek</u> Signature <u>August 11, 2009</u> Date Total number of pages including cover sheet: <u>3</u>	
--	--

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information:

Commissioner and Assistant Secretary of Patents and Trademarks
Box Assignments
Alexandria, VA 22313

08/13/2009 NJAMA1 00000031 7091188

01 FC:0021

40.00 OP

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

DOCKET NO. 2004_0422A

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

PATENT
REEL: 023079 FRAME: 0919

ASSIGNMENT OF INVENTION

In consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNORS: SUMITOMO CHEMICAL COMPANY, LIMITED
(Name of ASSIGNOR)

5-33, Kitahama 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan
Address

having been assigned its right, title and interest in the invention by virtue of an Assignment recorded at the U.S. Patent and Trademark Office on March 17, 2004

at Reel 015660, Frames 0398,

hereby sells, assigns and transfers to

ASSIGNEE: Dainippon Sumitomo Pharma Co., Ltd.
(Name of ASSIGNEE)

6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka-fu, 541-8524, Japan
Address

and the successors, assigns and legal representatives of the ASSIGNEE

- (X) the entire right, title and interest
- () an undivided _____ percent (_____%) interest for the United States and its territorial possessions
- () and in all foreign countries, including all rights to claim priority, in and to any and all improvements which are disclosed in the invention entitled:

STABILIZATION OF AMRUBICIN HYDROCHLORIDE

and which is found in

- (a) () U.S. patent application executed on even date herewith
- (b) () U.S. patent application executed on

(c) () U.S. application serial no. _____ filed on _____.

(d) (X) U.S. patent no. 7,091,188 issued August 15, 2006

() A change of address to which correspondence is to be sent regarding patent maintenance fees is being sent separately.

(e) () and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any re-issue or re-examination thereof;

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purpose thereof.

IN WITNESS WHEREOF, I/WE have hereunto set hand and seal this 7th day of May, 2009
(Date of Signing)

Naoya Kanda

Signature of ASSIGNOR

Naoya KANDA

(Type or print name of ASSIGNOR)

Title Representative Director

Witness Masakazu Ichikawa Witness

K. Kanda

2004-0422A